食养银龄，洞察中老年营养健康消费图景 ——中国中老年营养健康食品专题报告 2025年4月 © 2025 灼识咨询版权所有。本文件提供的任何内容均系灼识咨询公司独有的高度机密性资料。 未经灼识咨询公司事先书面许可，任何人不得以任何方式擅自复制、传播、出版、引用、改编本文件内容 扫码添加CIC灼识小助手 联合发布方：量子之歌（NASDAQ：QSG） 量子之歌是中国领先的高品质生活服务提供商，致力于助力用户实现更美 好的生活与个人价值的提升。量子之歌深入理解成年用户的深层需求，并 依托强大的基础设施，开发了一系列易于理解、高性价比且便于获取的在 线课程。此外，量子之歌也特别关注中老年用户对健康生活的需求，并在 特定领域推出了一系列高品质的消费品和服务。 扫码添加CIC灼识小助手 发布方：灼识咨询 China Insights Consultancy 灼识咨询是一家知名咨询公司。其服务包括IPO行业咨询、商业尽职调查、战略咨询、 专家网络服务等。其咨询团队长期追踪消费品、互联网、大数据、高科技、能源电 力、供应链、人工智能、金融服务、医疗、教育、文娱、环境和楼宇科技、化工、 物流、工业、制造业、农业等方面最新的市场趋 ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 increased to approximately $394,000 compared to $335,000 for the same period last year, driven by an increase in grants revenue of approximately $210,000 from the Gates Foundation and CEPI [15] - Research and development expenses for Q1 2025 decreased to $495,000 from $523,000 year-over-year, reflecting a decrease in ongoing internal research projects [16] - General and administrative expenses decreased by 10.8% to $1,596,000 compared to $1,789,000 for the same period last year [17] - Net loss for Q1 2025 was $2,028,000 or $0.07 per share, compared to $2,010,000 or $0.07 per share for the same period last year [18] Business Line Data and Key Metrics Changes - The focus is on commercializing high-value recombinant enzymes and proteins, particularly in life sciences, nutrition, and industrial applications [4][5] - The top commercialization priority lies in the cell culture media space, valued at over $6.1 billion globally, growing at a 13% compound annual growth rate [6] - Significant progress is being made in the development of recombinant human serum albumin, with expectations for launch in Q3 2025 [7] Market Data and Key Metrics Changes - The animal-free dairy products market was valued at approximately $26.5 billion in 2023, with increasing partner interest in non-animal dairy proteins [9] - The nucleic acid tools market is projected to exceed $4 billion globally by 2028, with ongoing development of recombinant DNase-one and RNase-free enzymes [8] Company Strategy and Development Direction - The core growth strategy is centered on high-value life sciences, bioactives, ingredients, and industrial markets, aiming for sustainable growth in non-pharmaceutical sectors [5] - The company is focusing on product development rather than platform development, prioritizing commercialization-ready products [35][36] - Strategic partnerships are maintained in vaccine therapeutic developments, with collaborations with CEPI and the Gates Foundation [4][12] Management's Comments on Operating Environment and Future Outlook - Management emphasizes the importance of transitioning from a development stage to a product-driven revenue-generating enterprise [62] - The company is well-positioned to meet global demand for scalable and affordable animal-free precision engineered proteins and enzymes [63] - There is a commitment to strengthening the balance sheet to support near-term revenue growth and strategic objectives [18] Other Important Information - The company has cash and investment-grade securities of $7.4 million as of March 31, 2025, down from $9.4 million as of December 31, 2024 [18] - The company is participating in various funded programs, including a $4.5 million grant from CEPI and a $3 million program funded by the Gates Foundation [11][12] Q&A Session Summary Question: Can you explain the royalty arrangement with Fermbox? - The profit split is significant for both companies, and revenue sharing will begin immediately as sales start rolling in [22][23] Question: What is the progress on the albumin arrangement? - No advanced orders have been placed yet; sampling is expected to begin in Q2 2025 [24] Question: Will there be opportunities for Fermbox to bid on other contracts? - There are ongoing evaluations for additional contracts in both government and private sectors [27] Question: When will the company start spending less on research and more on revenue-generating areas? - The company is currently reprioritizing resources towards non-pharmaceutical sectors for revenue generation [34][36] Question: What product in the non-dairy applications portfolio has the best margins? - Lactoferrin has the highest margin potential, while alpha-lactalbumin has the largest market potential [40][41] Question: Is there any quantifiable tariff problem for the company? - Currently, there are no significant tariff issues, and there may be potential opportunities with onshoring [50] Question: Will the albumin and dairy enzymes be produced in the U.S.? - Yes, both products are being produced domestically, which mitigates tariff concerns [54][55]

Core Insights - The 29th CBE China Beauty Expo highlighted the growing opportunities in the anti-aging market, with Tmall International showcasing its global resource integration capabilities alongside the Norwegian high-end dietary nutrition brand NYO3 [1][3] Industry Trends - The anti-aging market in China is expected to exceed 150 billion yuan by 2026, with oral anti-aging products becoming the primary focus. Antioxidant ingredients are gaining importance, and the demographic of consumers is shifting younger, with those aged 25-30 becoming the main consumer group [3][6] Company Strategy - Tmall International maintains strict brand entry standards, ensuring the authenticity and compliance of cross-border health products. NYO3 has successfully passed these rigorous checks and is recognized as the leading anti-aging brand in Northern Europe [5][6] Product Launch and Performance - NYO3's new product, Ageless, combines various premium ingredients and has achieved a 98% absorption rate. It quickly became the top-selling oral beauty product on Tmall International within its first month of launch [8][10] Consumer Engagement - NYO3 plans to launch a "90-day skin rejuvenation program" during the 618 shopping festival, offering a full refund if customers are not satisfied with the results. This initiative reflects the brand's commitment to understanding and meeting consumer needs [10][11] Global Expansion - NYO3 aims to leverage Tmall's resources for global growth, particularly in the Asia-Pacific region, while adhering to Norwegian production standards. The collaboration is expected to enhance brand reputation and sales, contributing to sustainable growth in the global health industry [13]

继体能班、跳绳冲刺班后，本用于马拉松等竞技体育的营养补剂开始打起中小学体考的主意。近期，有 家长向北京商报记者反映，随着中考体考的临近，自己被淘宝、抖音、小红书等平台不断推送"体考神 器""提升耐力""快速冲刺"等宣传直击家长对孩子成绩的焦虑，甚至有些产品更打出了"体考包、加速 器，早喝拿满分"的宣传语。部分产品销量轻松突破万件，甚至稳坐平台健康类补剂第一名。好评区充 斥着"成绩飞升"的夸张描述。诱人宣传、超高销量的另一面，是不断有家长反馈学生服用后频发健康警 报——心跳过速、肠胃紊乱、失眠等接连出现。当正常的体育测试被异化为商业狂欢，谁来守住青少年 的健康底线？ 玄幻的"体考小红瓶" 在与先生、同学家长连续三个晚上讨论怎样做好体考冲刺后，徐诺的手机开始被频繁推送"体考神器"。 小红书，首当其冲。在"五一"期间，徐诺每天打开小红书，第一页永远有一条名为诺特兰德小红瓶的产 品，有的时候是加V的体育教练，有的时候是机构，主要内容都是"考前30分钟喝下，成绩拉满不是 梦"。 不仅如此，在抖音平台、淘宝网，给徐诺的推荐产品也都是类似的"小红瓶"、体考神器，牌子各有不 同，内容大致相当，徐诺甚至有一段时间考虑过手机是否 ...

体重与人体健康状况密切相关，超重与肥胖症不仅是慢性疾病中的独立病种，更容易诱发其他慢性 疾病。通过加强科学体重管理，引导公众建立健康生活方式，进而降低肥胖及相关并发症的发病风险与 潜在危害，成为构建健康社会的重要路径。 在2025年"世界防治肥胖日"到来之际，北京大学公共卫生学院营养与食品卫生学教授马冠生、北大 人民医院临床营养科主任柳鹏、康宝莱全球产品创新中心负责人方玮就养成科学减重方法、做好终身体 重管理等话题展开交流。他们倡导全社会推行健康的生活方式，提升公众体重管理意识，全面培养个人 科学减重能力，及早预防、控制超重肥胖，塑造轻盈、健康的人生。 0:00 / 50:43 提升体重管理意识 深化健康中国建设内涵 近年来，国家卫生健康委员会等部门陆续出台了"体重管理年"三年行动等一系列聚焦"减重"的具体 举措，旨在提升全民体重管理意识和技能，预防和控制超重肥胖问题。 马冠生认为，作为常见的公共卫生问题，肥胖影响着人们的生命健康和生活质量。"体重过高或过 低都是不健康的表现，特别是肥胖或超重肥胖，可能导致患上各类慢病。国家卫生健康委发布的《体重 管理指导原则（2024年版）》指出，有研究预测，如果得不到有效 ...

Group 1 - European multinational companies remain optimistic about China's economic prospects despite complex international circumstances, as evidenced by their continued investment and participation in major trade events like the Shanghai International Auto Show [1][2] - The bilateral trade volume between China and the EU has significantly increased from $2.4 billion at the time of diplomatic relations establishment in 1975 to $780 billion today, highlighting the strong economic ties and mutual benefits [2] - Companies like BMW and Danfoss are actively engaging in innovative collaborations with Chinese firms, recognizing China's rapid innovation pace and talent pool, which enhances their competitive edge in the global market [3][5] Group 2 - The Chinese government has introduced measures to further open up its market and attract foreign investment, including the "2025 Action Plan for Stabilizing Foreign Investment," which aims to reduce entry restrictions and improve the business environment for foreign companies [4] - European companies, such as Danfoss, have reported strong growth in their operations in China, particularly in sectors like data centers and energy storage, indicating a positive outlook for future collaborations [5]

A股上市公司2024年年报收官，十大"盈利王""增长王"浮出水面。 数据显示，剔除金融股影响，2024年，中国石油、中国移动、中国海油、贵州茅台、中国神华、宁德时 代、中国石化、中远海控、中国建筑、比亚迪为A股十大"盈利王"。 剔除金融股及扭亏股影响，2024年，正丹股份、广西能源、思特威-W、华北制药、安迪苏、国机汽 车、三湘印象、德明利、沪光股份、七彩化学为A股十大"增长王"。 十大"盈利王"均计划现金分红 "三桶油"中，中国石油、中国海油均跻身十大"盈利王"。 中国石油2024年实现归母净利润1646.8亿元， 同比增长2.0%；中国海油2024年实现归母净利润1379.36亿元，同比增长11.4%。 十大"盈利王"均计划进行现金分红。贵州茅台2024年实现营业总收入1741.44亿元，同比增长15.66%； 实现归母净利润862.28亿元，同比增长15.38%，公司拟10派276.24元。2024年度贵州茅台将合计派发现 金分红647亿元（其中300亿元已经派发）。 贵州茅台在公告中表示，2025年主要目标是实现营业总收入较上年度增长9%左右，完成固定资产投资 47.11亿元。 此外，宁德时代宣布拟1 ...

Herbalife (HLF) Q1 2025 Earnings Call April 30, 2025 05:30 PM ET Company Participants Erin Banyas - Vice President - Head of Investor RelationsStephan Gratziani - CEOJohn DeSimone - Chief Financial OfficerJohn Baumgartner - Managing Director, Equity ResearchRobert Rigby - AssociateHale Holden - Managing DirectorDouglas Lane - Head of Consumer Products Conference Call Participants None - Analyst Operator Good afternoon, and thank you for joining the First Quarter twenty twenty five Earnings Conference Call f ...

主营业务销售强劲，动物营养龙头安迪苏（600299）(600299.SH)业绩持续高增。 4月28日，蓝星安迪苏股份有限公司(下称"安迪苏")公布了2025年一季度业绩报告。报告期内，公司营 收同比增长23%至43亿元，毛利同比增长14%至12.7亿元，净利润同比增长67.9%至4.65亿元。 据了解，安迪苏是一家具有80余年发展历史的全球化动物营养添加剂龙头企业。近年来，安迪苏一直实 施"双支柱"战略，即在不断巩固蛋氨酸行业领先地位的同时，加快特种业务的发展。 长江商报记者注意到，蛋氨酸是安迪苏的主要产品之一，2025年一季度，安迪苏功能性产品实现营收 33.18亿元，同比增长29%。其中，蛋氨酸业务销量同比增长24%，创单季销量纪录，这主要源于液体蛋 氨酸市场渗透率持续提升。 数据显示，2025年一季度，安迪苏两大"支柱业务"均实现增长。 公司功能性产品实现营收33.18亿元，同比增长29%，该业务毛利率为26%。其中，蛋氨酸业务销量同比 增长24%，创单季销量纪录。这主要源于密切监测产品价格并采取灵活机动的价格管理战略；所有工厂 均实现优异的生产稳定性和高产能利用率，抵消了原材料价格上涨带来的不利影响等 ...

Core Insights - Arla Foods Ingredients is focusing on the medical nutrition sector with its innovative Micellar Casein Isolate (MCI) solutions to meet the growing demand for high-quality medical nutrition ingredients [1][3] Group 1: Product Development - The new product, Lacprodan MicelPure® Medical, is designed specifically to meet the unique nutritional needs of medical nutrition [3][5] - The Lacprodan MicelPure® series includes various MCI solutions, such as standard MCI for oral nutritional supplements and tube feeding products, and a quick-dissolve version for immediate consumption [5][6] Group 2: Market Trends - Malnutrition is a key driver of innovation in the global medical nutrition market, which is projected to grow at a compound annual growth rate (CAGR) of 5% from 2024 to 2027 [4] - An estimated 20-70% of cancer patients and 30-70% of elderly patients face malnutrition issues, impacting their quality of life and increasing mortality risk [4][6] Group 3: Product Features - Lacprodan MicelPure® maintains low viscosity at high protein concentrations and has a neutral milk flavor, enhancing patient acceptance [5][6] - The products are designed to be heat-stable and adaptable for various packaging formats, suitable for long-term storage [5][6] Group 4: Company Overview - Arla Foods Ingredients is a leading global supplier of nutritional solutions, focusing on infant nutrition, medical nutrition, sports nutrition, and health foods [7] - The company emphasizes innovation in nutrition, collaboration with global partners, and a commitment to sustainable development [7]